Moreover, almost half of enrolled patients had surgical resection prior to clinical trial enrollment resulting in a smaller volume of recurrent tumor which may impact response to study treatment.33 Finally, the patient population is heterogeneous and included patients who have been heavily pretreated or have a tumor harboring IDH mutation (2 subjects), which in conjunction with inter-tumor and intra-tumor heterogeneities may have a significant difference in baseline prognosis. Here, IDH1 is linked to neoplasm.